Giuseppe Legname

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7523752/publications.pdf

Version: 2024-02-01

208 papers	11,021 citations	36303 51 h-index	36028 97 g-index
225 all docs	225 docs citations	225 times ranked	9157 citing authors

#	Article	IF	Citations
1	Synthetic Mammalian Prions. Science, 2004, 305, 673-676.	12.6	956
2	Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature, 2001, 412, 739-743.	27.8	503
3	Pathway Complexity of Prion Protein Assembly into Amyloid. Journal of Biological Chemistry, 2002, 277, 21140-21148.	3.4	393
4	Binding of neural cell adhesion molecules (N-CAMs) to the cellular prion protein. Journal of Molecular Biology, 2001, 314, 1209-1225.	4.2	328
5	Copper Coordination in the Full-Length, Recombinant Prion Proteinâ€. Biochemistry, 2003, 42, 6794-6803.	2.5	278
6	Microglia convert aggregated amyloid-Î² into neurotoxic forms through the shedding of microvesicles. Cell Death and Differentiation, 2014, 21, 582-593.	11.2	219
7	Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nature Biotechnology, 2002, 20, 1147-1150.	17.5	215
8	A Change in the Conformation of Prions Accompanies the Emergence of a New Prion Strain. Neuron, 2002, 34, 921-932.	8.1	214
9	Folding of Prion Protein to Its Native Î±-Helical Conformation Is under Kinetic Control. Journal of Biological Chemistry, 2001, 276, 19687-19690.	3.4	209
10	Prion detection by an amyloid seeding assay. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20914-20919.	7.1	205
11	Glia-to-neuron transfer of miRNAs via extracellular vesicles: a new mechanism underlying inflammation-induced synaptic alterations. Acta Neuropathologica, 2018, 135, 529-550.	7.7	196
12	Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19105-19110.	7.1	194
13	Design and construction of diverse mammalian prion strains. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20417-20422.	7.1	191
14	Cytosolic Prion Protein in Neurons. Journal of Neuroscience, 2003, 23, 7183-7193.	3.6	190
15	The influence of the srcâ€family kinases, Lck and Fyn, on T cell differentiation, survival and activation. Immunological Reviews, 2003, 191, 107-118.	6.0	178
16	Strain-specified characteristics of mouse synthetic prions. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2168-2173.	7.1	178
17	Recombinant prion protein induces rapid polarization and development of synapses in embryonic rat hippocampal neurons in vitro. Journal of Neurochemistry, 2005, 95, 1373-1386.	3.9	155
18	Locally Disordered Conformer of the Hamster Prion Protein:Â A Crucial Intermediate to PrPSc?â€. Biochemistry, 2002, 41, 12277-12283.	2.5	154

#	Article	IF	Citations
19	Prions in skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3812-3817.	7.1	149
20	Protease-Sensitive Synthetic Prions. PLoS Pathogens, 2010, 6, e1000736.	4.7	148
21	Copper-catalyzed oxidation of the recombinant SHa(29-231) prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 7170-7175.	7.1	139
22	Continuous Quinacrine Treatment Results in the Formation of Drug-Resistant Prions. PLoS Pathogens, 2009, 5, e1000673.	4.7	135
23	Inducible Expression of a p56Lck Transgene Reveals a Central Role for Lck in the Differentiation of CD4 SP Thymocytes. Immunity, 2000, 12, 537-546.	14.3	132
24	Doppel-induced cerebellar degeneration in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 15288-15293.	7.1	130
25	Single-chain ribosome inactivating proteins from plants depurinateEscherichia coli23S ribosomal RNA. FEBS Letters, 1991, 290, 65-68.	2.8	127
26	Long-Term Survival But Impaired Homeostatic Proliferation of Naive T Cells in the Absence of p56lck. Science, 2000, 290, 127-131.	12.6	114
27	Structureâ^'Activity Relationship Study of Prion Inhibition by 2-Aminopyridine-3,5-dicarbonitrile-Based Compounds:â€‰ Parallel Synthesis, Bioactivity, and in Vitro Pharmacokinetics. Journal of Medicinal Chemistry, 2007, 50, 65-73.	6.4	112
28	Functionalized gold nanoparticles: a detailed in vivo multimodal microscopic brain distribution study. Nanoscale, 2010, 2, 2826.	5.6	108
29	Efficient RT-QuIC seeding activity for Î±-synuclein in olfactory mucosa samples of patients with Parkinsonâ€™s disease and multiple system atrophy. Translational Neurodegeneration, 2019, 8, 24.	8.0	106
30	Î±-Synuclein Amyloids Hijack Prion Protein to Gain Cell Entry, Facilitate Cell-to-Cell Spreading and Block Prion Replication. Scientific Reports, 2017, 7, 10050.	3.3	105
31	Prion Protein and Copper Cooperatively Protect Neurons by Modulating NMDA Receptor Through S-nitrosylation. Antioxidants and Redox Signaling, 2015, 22, 772-784.	5.4	101
32	Probing the N-Terminal Î²-Sheet Conversion in the Crystal Structure of the Human Prion Protein Bound to a Nanobody. Journal of the American Chemical Society, 2014, 136, 937-944.	13.7	97
33	Identification of Two Prion Protein Regions That Modify Scrapie Incubation Time. Journal of Virology, 2001, 75, 1408-1413.	3.4	95
34	Î±â€Synuclein RTâ€QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. Annals of Clinical and Translational Neurology, 2019, 6, 2120-2126.	3.7	87
35	Antiâ€GM ₁ IgM antibodies in motor neuron disease and neuropathy. Neurology, 1990, 40, 1747-1747.	1.1	87
36	Anti-myelin-associated glycoprotein IgM antibody titers in neuropathy associated with macroglobulinemia. Annals of Neurology, 1989, 26, 543-550.	5.3	84

#	Article	IF	Citations
37	Oxidation of methionine residues in the prion protein by hydrogen peroxide. Archives of Biochemistry and Biophysics, 2004, 432, 188-195.	3.0	82
38	Tau-Centric Multitarget Approach for Alzheimerâ€™s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3Î² and Tau-Aggregation Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 7640-7656.	6.4	81
39	The peculiar nature of unfolding of the human prion protein. Protein Science, 2004, 13, 586-595.	7.6	72
40	NMR Structure of the Human Prion Protein with the Pathological Q212P Mutation Reveals Unique Structural Features. PLoS ONE, 2010, 5, e11715.	2.5	71
41	Spontaneous generation of anchorless prions in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 21223-21228.	7.1	68
42	Clinical and neuropathological phenotype associated with the novel V189I mutation in the prion protein gene. Acta Neuropathologica Communications, 2019, 7, 1.	5.2	68
43	Common Structural Traits across Pathogenic Mutants of the Human Prion Protein and Their Implications for Familial Prion Diseases. Journal of Molecular Biology, 2011, 411, 700-712.	4.2	66
44	In vitro aggregation assays for the characterization of Î±-synuclein prion-like properties. Prion, 2014, 8, 19-32.	1.8	66
45	Defined Î±-synuclein prion-like molecular assemblies spreading in cell culture. BMC Neuroscience, 2014, 15, 69.	1.9	66
46	Opposite Structural Effects of Epigallocatechin-3-gallate and Dopamine Binding to Î±-Synuclein. Analytical Chemistry, 2016, 88, 8468-8475.	6.5	61
47	Immobilized prion protein undergoes spontaneous rearrangement to a conformation having features in common with the infectious form. EMBO Journal, 2001, 20, 1547-1554.	7.8	58
48	Differential overexpression of SERPINA3 in human prion diseases. Scientific Reports, 2017, 7, 15637.	3.3	58
49	Toward the Molecular Basis of Inherited Prion Diseases: NMR Structure of the Human Prion Protein with V210I Mutation. Journal of Molecular Biology, 2011, 412, 660-673.	4.2	57
50	Motor neuron disease in a patient with a monoclonal IgMk directed against GM1, GD1b, and high-molecular-weight neural-specific glycoproteins. Annals of Neurology, 1990, 28, 190-194.	5.3	56
51	Structural basis for the protective effect of the human prion protein carrying the dominant-negative E219K polymorphism. Biochemical Journal, 2012, 446, 243-251.	3.7	56
52	TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients. Brain Communications, 2020, 2, fcaa142.	3.3	55
53	Thioaptamer Interactions with Prion Proteins: Sequence-specific and Non-specific Binding Sites. Journal of Molecular Biology, 2007, 369, 1001-1014.	4.2	54
54	A new approach to follow a single extracellular vesicleâ€”cell interaction using optical tweezers. BioTechniques, 2016, 60, 35.	1.8	54

#	Article	IF	Citations
55	Prion Proteins with Pathogenic and Protective Mutations Show Similar Structure and Dynamics. Biochemistry, 2009, 48, 8120-8128.	2.5	53
56	Modulation of Alpha-Synuclein Aggregation by Dopamine Analogs. PLoS ONE, 2010, 5, e9234.	2.5	52
57	Differential Inhibition of Prion Propagation by Enantiomers of Quinacrine. Laboratory Investigation, 2003, 83, 837-843.	3.7	50
58	A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimerâ€™s and Prion Diseases. ACS Medicinal Chemistry Letters, 2013, 4, 225-229.	2.8	48
59	QUINACRINE IS MAINLY METABOLIZED TO MONO-DESETHYL QUINACRINE BY CYP3A4/5 AND ITS BRAIN ACCUMULATION IS LIMITED BY P-GLYCOPROTEIN. Drug Metabolism and Disposition, 2006, 34, 1136-1144.	3.3	46
60	Structural facets of diseaseâ€linked human prion protein mutants: A molecular dynamic study. Proteins: Structure, Function and Bioinformatics, 2010, 78, 3270-3280.	2.6	46
61	Compact conformations of Î±â€synuclein induced by alcohols and copper. Proteins: Structure, Function and Bioinformatics, 2011, 79, 611-621.	2.6	45
62	Characterization of a saporin isoform with lower ribosome-inhibiting activity. Biochemical Journal, 1997, 322, 719-727.	3.7	44
63	Cooperative Binding of Dominant-Negative Prion Protein to Kringle Domains. Journal of Molecular Biology, 2003, 329, 323-333.	4.2	42
64	Detection of prion seeding activity in the olfactory mucosa of patients with Fatal Familial Insomnia. Scientific Reports, 2017, 7, 46269.	3.3	41
65	Prion and Prion-Like Protein Strains: Deciphering the Molecular Basis of Heterogeneity in Neurodegeneration. Viruses, 2019, 11, 261.	3.3	41
66	Immunoglobulins in Urine of Hamsters with Scrapie. Journal of Biological Chemistry, 2004, 279, 48817-48820.	3.4	40
67	PrP^CControls via Protein Kinase A the Direction of Synaptic Plasticity in the Immature Hippocampus. Journal of Neuroscience, 2013, 33, 2973-2983.	3.6	40
68	Human prions and plasma lipoproteins. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11312-11317.	7.1	39
69	Discovery of a Class of Diketopiperazines as Antiprion Compounds. ChemMedChem, 2010, 5, 1324-1334.	3.2	39
70	The non-octarepeat copper binding site of the prion protein is a key regulator of prion conversion. Scientific Reports, 2015, 5, 15253.	3.3	39
71	Identification of novel fluorescent probes preventing PrP Sc replication in prion diseases. European Journal of Medicinal Chemistry, 2017, 127, 859-873.	5.5	39
72	Structural Consequences of Copper Binding to the Prion Protein. Cells, 2019, 8, 770.	4.1	39

#	Article	IF	Citations
73	Elucidating the function of the prion protein. PLoS Pathogens, 2017, 13, e1006458.	4.7	38
74	Development of antibody fragments for immunotherapy of prion diseases. Biochemical Journal, 2009, 418, 507-515.	3.7	37
75	Copper Binding Regulates Cellular Prion Protein Function. Molecular Neurobiology, 2019, 56, 6121-6133.	4.0	37
76	Nucleotide sequence of cDNA coding for dianthin 30, a ribosome inactivating protein from Dianthus caryophyllus. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1991, 1090, 119-122.	2.4	36
77	Conformation of PrPC on the Cell Surface as Probed by Antibodies. Journal of Molecular Biology, 2003, 326, 475-483.	4.2	36
78	Pharmacokinetics of quinacrine in the treatment of prion disease. BMC Infectious Diseases, 2004, 4, 53.	2.9	35
79	Characterization of prion protein function by focal neurite stimulation. Journal of Cell Science, 2016, 129, 3878-3891.	2.0	35
80	Brain aging: A Ianusâ€faced player between health and neurodegeneration. Journal of Neuroscience Research, 2020, 98, 299-311.	2.9	35
81	Docking Ligands on Protein Surfaces: The Case Study of Prion Protein. Journal of Chemical Theory and Computation, 2009, 5, 2565-2573.	5.3	34
82	Small-Molecule Theranostic Probes: A Promising Future in Neurodegenerative Diseases. International Journal of Cell Biology, 2013, 2013, 1-19.	2.5	34
83	Probing Early Misfolding Events in Prion Protein Mutants by NMR Spectroscopy. Molecules, 2013, 18, 9451-9476.	3.8	34
84	Effect of an acute injection of melatonin on the basal secretion of hypophyseal hormones in prepubertal and pubertal healthy subjects. European Journal of Endocrinology, 1986, 111, 305-311.	3.7	33
85	Structural Rearrangements at Physiological pH: Nuclear Magnetic Resonance Insights from the V210I Human Prion Protein Mutant. Biochemistry, 2012, 51, 7465-7474.	2.5	33
86	Parallel Synthesis, Evaluation, and Preliminary Structureâ˜Activity Relationship of 2,5-Diamino-1,4-benzoquinones as a Novel Class of Bivalent Anti-Prion Compound. Journal of Medicinal Chemistry, 2010, 53, 8197-8201.	6.4	32
87	Effects of the Pathological Q212P Mutation on Human Prion Protein Non-Octarepeat Copper-Binding Site. Biochemistry, 2012, 51, 6068-6079.	2.5	32
88	Involvement of PrPC in kainate-induced excitotoxicity in several mouse strains. Scientific Reports, 2015, 5, 11971.	3.3	32
89	The uptake of tau amyloid fibrils is facilitated by the cellular prion protein and hampers prion propagation in cultured cells. Journal of Neurochemistry, 2020, 155, 577-591.	3.9	32
90	Prion Protein Accumulation in Lipid Rafts of Mouse Aging Brain. PLoS ONE, 2013, 8, e74244.	2.5	31

#	Article	IF	Citations
91	The N Terminus of the Prion Protein Mediates Functional Interactions with the Neuronal Cell Adhesion Molecule (NCAM) Fibronectin Domain. Journal of Biological Chemistry, 2016, 291, 21857-21868.	3.4	31
92	A novel class of potential prion drugs: preliminary in vitro and in vivo data for multilayer coated gold nanoparticles. Nanoscale, 2010, 2, 2724.	5.6	30
93	Prion protein and aging. Frontiers in Cell and Developmental Biology, 2014, 2, 44.	3.7	29
94	Conformational properties of intrinsically disordered proteins bound to the surface of silica nanoparticles. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 1556-1564.	2.4	29
95	The role of the prion protein in the internalization of Î±-synuclein amyloids. Prion, 2018, 12, 23-27.	1.8	29
96	Mycobacterium tuberculosis Chaperonin 10 Forms Stable Tetrameric and Heptameric Structures. Journal of Biological Chemistry, 1995, 270, 26159-26167.	3.4	28
97	Structural Determinants in Prion Protein Folding and Stability. Journal of Molecular Biology, 2014, 426, 3796-3810.	4.2	28
98	Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories. Molecular Neurodegeneration, 2021, 16, 82.	10.8	28
99	Effects of Tetrahydrocannabinol on Melatonin Secretion in Man. Hormone and Metabolic Research, 1986, 18, 77-78.	1.5	27
100	Neurodevelopmental expression and localization of the cellular prion protein in the central nervous system of the mouse. Journal of Comparative Neurology, 2010, 518, 1879-1891.	1.6	27
101	A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation. European Journal of Medicinal Chemistry, 2012, 48, 206-213.	5.5	27
102	Hemoglobin mRNA Changes in the Frontal Cortex of Patients with Neurodegenerative Diseases. Frontiers in Neuroscience, 2018, 12, 8.	2.8	26
103	Brain delivery of AAV9 expressing an anti-PrP monovalent antibody delays prion disease in mice. Prion, 2012, 6, 383-390.	1.8	25
104	Approaches for discovering anti-prion compounds: lessons learned and challenges ahead. Expert Opinion on Drug Discovery, 2015, 10, 389-397.	5.0	25
105	Methionine oxidation in Î±-synuclein inhibits its propensity for ordered secondary structure. Journal of Biological Chemistry, 2019, 294, 5657-5665.	3.4	25
106	Prion and doppel proteins bind to granule cells of the cerebellum. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 16285-16290.	7.1	24
107	Synthetic prions with novel strain-specified properties. PLoS Pathogens, 2015, 11, e1005354.	4.7	24
108	Early Growth Response (Egr)-1 Gene Induction in the Thymus in Response to TCR Ligation During Early Steps in Positive Selection Is Not Required for CD8 Lineage Commitment. Journal of Immunology, 2000, 165, 2444-2450.	0.8	22

#	Article	IF	Citations
109	A novel expression system for production of soluble prion proteins in E. coli. Microbial Cell Factories, 2012, 11, 6.	4.0	22
110	Structural evidence for the critical role of the prion protein hydrophobic region in forming an infectious prion. PLoS Pathogens, 2019, 15, e1008139.	4.7	22
111	Anti-CD30 immunotoxins with native and recombinant dianthin 30. Cancer Immunology, Immunotherapy, 1995, 40, 109-114.	4.2	21
112	Oriented Immobilization of Prion Protein DemonstratedviaPrecise Interfacial Nanostructure Measurements. ACS Nano, 2010, 4, 6607-6616.	14.6	21
113	Epitope mapping of a PrP(Sc)-specific monoclonal antibody: Identification of a novel C-terminally truncated prion fragment. Molecular Immunology, 2011, 48, 746-750.	2.2	21
114	Gene expression profiling of brains from bovine spongiform encephalopathy (BSE)-infected cynomolgus macaques. BMC Genomics, 2014, 15, 434.	2.8	21
115	Developmental influence of the cellular prion protein on the gene expression profile in mouse hippocampus. Physiological Genomics, 2011, 43, 711-725.	2.3	20
116	Expression inEscherichia coli, purification and functional activity of recombinant human chaperonin 10. FEBS Letters, 1995, 361, 211-214.	2.8	19
117	Synthesis and evaluation of a library of 2,5-bisdiamino-benzoquinone derivatives as probes to modulate proteinâ€“protein interactions in prions. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1866-1868.	2.2	19
118	The role of Bax and caspase-3 in doppel-induced apoptosis of cerebellar granule cells. Prion, 2012, 6, 309-316.	1.8	19
119	Astrocytesâ€derived extracellular vesicles in motion at the neuron surface: Involvement of the prion protein. Journal of Extracellular Vesicles, 2021, 10, e12114.	12.2	19
120	Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits. Expert Opinion on Drug Discovery, 2012, 7, 245-259.	5.0	18
121	SAXS structural study of PrPScreveals ~11 nm diameter of basic double intertwined fibers. Prion, 2013, 7, 496-500.	1.8	18
122	Serpin Signatures in Prion and Alzheimerâ€™s Diseases. Molecular Neurobiology, 2022, 59, 3778-3799.	4.0	18
123	Structural Insights into Alternate Aggregated Prion Protein Forms. Journal of Molecular Biology, 2009, 393, 1033-1042.	4.2	17
124	Aberrant ERK 1/2 complex activation and localization in scrapie-infected GT1-1 cells. Molecular Neurodegeneration, 2010, 5, 29.	10.8	17
125	Combining in-situ proteolysis and microseed matrix screening to promote crystallization of PrPc-nanobody complexes. Protein Engineering, Design and Selection, 2011, 24, 737-741.	2.1	17
126	Expression pattern of perilipins in human brain during aging and in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	17

#	Article	IF	Citations
127	Identification and cloning of human chaperonin 10 homologue. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1994, 1218, 478-480.	2.4	16
128	Genetic grafting of membrane-acting peptides to the cytotoxin dianthin augments its ability to de-stabilize lipid bilayers and enhances its cytotoxic potential as the component of transferrin-toxin conjugates. , 2000, 86, 582-589.		16
129	Infrared Microspectroscopy: A Multiple-Screening Platform for Investigating Single-Cell Biochemical Perturbations upon Prion Infection. ACS Chemical Neuroscience, 2011, 2, 160-174.	3.5	16
130	Prion Protein Interaction with Soil Humic Substances: Environmental Implications. PLoS ONE, 2014, 9, e100016.	2.5	16
131	Iron-mediated interaction of alpha synuclein with lipid raft model membranes. Nanoscale, 2020, 12, 7631-7640.	5.6	16
132	Investigating the Conformational Stability of Prion Strains through a Kinetic Replication Model. PLoS Computational Biology, 2009, 5, e1000420.	3.2	15
133	Prion Protein-Specific Antibodies-Development, Modes of Action and Therapeutics Application. Viruses, 2014, 6, 3719-3737.	3.3	15
134	Synthetic prions and other human neurodegenerative proteinopathies. Virus Research, 2015, 207, 25-37.	2.2	15
135	On the role of the cellular prion protein in the uptake and signaling of pathological aggregates in neurodegenerative diseases. Prion, 2020, 14, 257-270.	1.8	15
136	Role of Prion Disease-Linked Mutations in the Intrinsically Disordered N-Terminal Domain of the Prion Protein. Journal of Chemical Theory and Computation, 2013, 9, 5158-5167.	5.3	14
137	In Absence of the Cellular Prion Protein, Alterations in Copper Metabolism and Copper-Dependent Oxidase Activity Affect Iron Distribution. Frontiers in Neuroscience, 2016, 10, 437.	2.8	14
138	The Priority position paper: Protecting Europe's food chain from prions. Prion, 2016, 10, 165-181.	1.8	13
139	Prions Strongly Reduce NMDA Receptor S-Nitrosylation Levels at Pre-symptomatic and Terminal Stages of Prion Diseases. Molecular Neurobiology, 2019, 56, 6035-6045.	4.0	13
140	The Cellular Prion Protein Increases the Uptake and Toxicity of TDP-43 Fibrils. Viruses, 2021, 13, 1625.	3.3	13
141	Expression and Activity of Pre-dianthin 30 and Dianthin 30. Biochemical and Biophysical Research Communications, 1993, 192, 1230-1237.	2.1	12
142	De novo mammalian prion synthesis. Prion, 2009, 3, 213-219.	1.8	12
143	New insights into structural determinants of prion protein folding and stability. Prion, 2015, 9, 119-124.	1.8	12
144	Dynamic molecular exchange and conformational transitions of alpha-synuclein at the nano-bio interface. International Journal of Biological Macromolecules, 2020, 154, 206-216.	7.5	12

#	Article	IF	Citations
145	NMR Structural Studies of Human Cellular Prion Proteins. Current Topics in Medicinal Chemistry, 2013, 13, 2407-2418.	2.1	12
146	Hybrid Lipoic Acid Derivatives to Attack Prion Disease on Multiple Fronts. ChemMedChem, 2011, 6, 601-605.	3.2	11
147	Progress towards structural understanding of infectious sheep PrP-amyloid. Prion, 2014, 8, 344-358.	1.8	11
148	Use of different RT-QuIC substrates for detecting CWD prions in the brain of Norwegian cervids. Scientific Reports, 2019, 9, 18595.	3.3	11
149	Deciphering Copper Coordination in the Mammalian Prion Protein Amyloidogenic Domain. Biophysical Journal, 2020, 118, 676-687.	0.5	11
150	Modulation of Prion by Small Molecules: From Monovalent to Bivalent and Multivalent Ligands. Current Topics in Medicinal Chemistry, 2013, 13, 2491-2503.	2.1	11
151	Chronic Î±-Synuclein Accumulation in Rat Hippocampus Induces Lewy Bodies Formation and Specific Cognitive Impairments. ENeuro, 2020, 7, ENEURO.0009-20.2020.	1.9	11
152	A system-level approach for deciphering the transcriptional response to prion infection. Bioinformatics, 2011, 27, 3407-3414.	4.1	10
153	Novel regulators of PrP^C expression as potential therapeutic targets in prion diseases. Expert Opinion on Therapeutic Targets, 2020, 24, 759-776.	3.4	10
154	Tackling prion diseases: a review of the patent landscape. Expert Opinion on Therapeutic Patents, 2021, 31, 1097-1115.	5.0	10
155	Whole Blood Gene Expression Profiling in Preclinical and Clinical Cattle Infected with Atypical Bovine Spongiform Encephalopathy. PLoS ONE, 2016, 11, e0153425.	2.5	10
156	The mechanisms of humic substances self-assembly with biological molecules: The case study of the prion protein. PLoS ONE, 2017, 12, e0188308.	2.5	10
157	Early structural features in mammalian prion conformation conversion. Prion, 2012, 6, 37-39.	1.8	9
158	Dominant-negative effects in prion diseases: insights from molecular dynamics simulations on mouse prion protein chimeras. Journal of Biomolecular Structure and Dynamics, 2013, 31, 829-840.	3.5	9
159	Rational approach to an antiprion compound with a multiple mechanism of action. Future Medicinal Chemistry, 2015, 7, 2113-2120.	2.3	9
160	The Prion Concept and Synthetic Prions. Progress in Molecular Biology and Translational Science, 2017, 150, 147-156.	1.7	9
161	Characterization of four new monoclonal antibodies against the distal N-terminal region of PrP^c. PeerJ, 2015, 3, e811.	2.0	9
162	Crystallization and preliminary X-ray diffraction analysis of a specific VHH domain against mouse prion protein. Acta Crystallographica Section F: Structural Biology Communications, 2010, 66, 1644-1646.	0.7	8

#	Article	IF	Citations
163	Site-specific analysis of N-glycans from different sheep prion strains. PLoS Pathogens, 2021, 17, e1009232.	4.7	8
164	Therapeutic strategies for identifying small molecules against prion diseases. Cell and Tissue Research, 2023, 392, 337-347.	2.9	8
165	Substrate recognition by ribosome-inactivating protein studied by molecular modeling and molecular electrostatic potentials. Journal of Molecular Graphics, 1995, 13, 83-88.	1.1	7
166	Evidence for GroES Acting as a Transcriptional Regulator. Biochemical and Biophysical Research Communications, 1996, 229, 412-418.	2.1	7
167	Gene expression profiling to identify druggable targets in prion diseases. Expert Opinion on Drug Discovery, 2010, 5, 177-202.	5.0	7
168	Synthetic Prion Selection and Adaptation. Molecular Neurobiology, 2019, 56, 2978-2989.	4.0	7
169	Novel screening approaches for human prion diseases drug discovery. Expert Opinion on Drug Discovery, 2019, 14, 983-993.	5.0	7
170	Depicting Conformational Ensembles of Î±-Synuclein by Single Molecule Force Spectroscopy and Native Mass Spectroscopy. International Journal of Molecular Sciences, 2019, 20, 5181.	4.1	7
171	Cell-free amplification of prions: Where do we stand?. Progress in Molecular Biology and Translational Science, 2020, 175, 325-358.	1.7	7
172	In silico/inÂvitro screening and hit evaluation identified new phenothiazine anti-prion derivatives. European Journal of Medicinal Chemistry, 2020, 196, 112295.	5.5	7
173	Structural Studies of Prion Proteins and Prions. , 2012, , 289-317.		7
174	Prion Protein Paralog Doppel Protein Interacts with Alpha-2-Macroglobulin: A Plausible Mechanism for Doppel-Mediated Neurodegeneration. PLoS ONE, 2009, 4, e5968.	2.5	7
175	Humic substances interfere with detection of pathogenic prion protein. Soil Biology and Biochemistry, 2014, 68, 309-316.	8.8	6
176	Cochaperonins Are Histone-Binding Proteins. Biochemical and Biophysical Research Communications, 1995, 206, 260-265.	2.1	5
177	Aged PrP null mice show defective processing of neuregulins in the peripheral nervous system. Molecular and Cellular Neurosciences, 2011, 47, 28-35.	2.2	5
178	Prion Efficiently Replicates in Î±-Synuclein Knockout Mice. Molecular Neurobiology, 2019, 56, 7448-7457.	4.0	5
179	Unique Structural Features of Mule Deer Prion Protein Provide Insights into Chronic Wasting Disease. ACS Omega, 2019, 4, 19913-19924.	3.5	5
180	The role of the cellular prion protein in the uptake and toxic signaling of pathological neurodegenerative aggregates. Progress in Molecular Biology and Translational Science, 2020, 175, 297-323.	1.7	5

#	Article	IF	Citations
181	The Alpha-Synuclein RT-QuIC Products Generated by the Olfactory Mucosa of Patients with Parkinsonâ€™s Disease and Multiple System Atrophy Induce Inflammatory Responses in SH-SY5Y Cells. Cells, 2022, 11, 87.	4.1	5
182	Innovative Non-PrP-Targeted Drug Strategy Designed to Enhance Prion Clearance. Journal of Medicinal Chemistry, 2022, 65, 8998-9010.	6.4	5
183	Mycobacterial Cpn10 promotes recognition of the mammalian homologue by a mycobacterium-specific antiserum. Biochimica Et Biophysica Acta - Molecular Cell Research, 1998, 1403, 151-157.	4.1	4
184	Mapping the Prion Protein Distribution in Marsupials: Insights from Comparing Opossum with Mouse CNS. PLoS ONE, 2012, 7, e50370.	2.5	4
185	PMCA-generated prions from the olfactory mucosa of patients with Fatal Familial Insomnia cause prion disease in mice. ELife, 2021, 10, .	6.0	4
186	The E3 Ubiquitin Ligase TRAF6 Interacts with the Cellular Prion Protein and Modulates Its Solubility and Recruitment to Cytoplasmic p62/SQSTM1-Positive Aggresome-Like Structures. Molecular Neurobiology, 2022, , 1.	4.0	4
187	PMCA-Based Detection of Prions in the Olfactory Mucosa of Patients With Sporadic Creutzfeldtâ€“Jakob Disease. Frontiers in Aging Neuroscience, 2022, 14, 848991.	3.4	4
188	Effects of peptidyl-prolyl isomerase 1 depletion in animal models of prion diseases. Prion, 2018, 12, 127-137.	1.8	3
189	NMDA Receptor and L-Type Calcium Channel Modulate Prion Formation. Cellular and Molecular Neurobiology, 2021, 41, 191-198.	3.3	3
190	Heterologous expression, purification, activity and conformational studies of different forms of dianthin 30. Biomedical Peptides, Proteins & Nucleic Acids: Structure, Synthesis & Biological Activity, 1995, 1, 61-8.	0.1	3
191	Anti-CD30 immunotoxins with native and recombinant dianthin 30. Cancer Immunology, Immunotherapy, 1995, 40, 109-114.	4.2	2
192	Editorial (Thematic Issue: Recent Advances of Biology and Medicinal Chemistry of Prion Protein and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.1	2
193	Volume 192, Number 3 (1993), in the article "Expression and Activity of Pre-dianthin 30 and Dianthin 30," by Giuseppe Legname, Gianni Gromo, J. Michael Lord, Nicoletta Monzini, and Daniela Modena, pages 1230-1237. Biochemical and Biophysical Research Communications, 1993, 195, 506.	2.1	1
194	Synthetic Mammalian Prions. Neuromethods, 2017, , 209-228.	0.3	1
195	Profiling Dopamine-Induced Oxidized Proteoforms of Î²-synuclein by Top-Down Mass Spectrometry. Antioxidants, 2021, 10, 893.	5.1	1
196	Pathogenesis of Prion Diseases. , 2007, , 125-146.		1
197	De novo prions. F1000 Biology Reports, 2010, 2, .	4.0	1
198	Copper Binding Regulates Cellular Prion Protein Function. FASEB Journal, 2018, 32, 805.4.	0.5	1

#	Article	IF	Citations
199	Prion receptors, prion internalization, intra- and inter-cellular transport. Progress in Molecular Biology and Translational Science, 2023, , 15-41.	1.7	1
200	Correction for Colby et al. , Prion detection by an amyloid seeding assay. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1774-1774.	7.1	0
201	Oriented Prion Protein Immobilization at Nanostructured Interfaces. Biophysical Journal, 2010, 98, 654a.	0.5	0
202	Effect of extracellular vesicles derived from distinct brain cells on AÎ² toxicity and assembly: focus on Microglia derived vesicles. SpringerPlus, 2015, 4, .	1.2	0
203	Prions. , 2016, , 839-844.		0
204	Preface. Progress in Molecular Biology and Translational Science, 2017, 150, xvii-xix.	1.7	0
205	How would defining Parkinsonâ€™s as a prion disease impact the search of a cure?. Expert Review of Neurotherapeutics, 2020, 20, 417-420.	2.8	0
206	Chemically Engineering the Prion Protein Using Stepwise SPPS and Expressed Protein Ligation. , 2001, , 818-819.		0
207	Pin1 and neurodegeneration: a new player for prion disorders?. AIMS Molecular Science, 2015, 2, 311-323.	0.5	0
208	Replacement of Residue H95 with Charged Amino Acids in the Prion Protein Decreases Prion Conversion Propensity. IFMBE Proceedings, 2020, , 255-259.	0.3	0